- PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
-
Provided herein are compounds of formula (I) as shown below, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
- -
-
Paragraph 0142; 0143; 0144
(2021/03/05)
-
- PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS
-
Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders.
- -
-
Paragraph 0136; 0137; 0138
(2021/03/05)
-
- PERK INHIBITING COMPOUNDS
-
Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
- -
-
Paragraph 0135-0137
(2021/03/05)
-
- PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS
-
Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):
- -
-
Page/Page column 54-56
(2021/11/20)
-
- PERK INHIBITORS FOR TREATING VIRAL INFECTIONS
-
Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):
- -
-
Page/Page column 66; 67
(2021/11/20)
-
- PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
-
Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I).
- -
-
Page/Page column 67-68
(2021/11/20)
-
- 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
-
Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (I) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.
- -
-
Paragraph 0093; 0110-0111
(2017/11/11)
-
- PXPd-catalyzed borylation of aniline derivatives
-
Addition of pinacolborane (HBO2C2Me4) to 2-iodoaniline can be catalyzed using a number of palladium complexes, including [(t-Bu)2PCl]2PdCl2 (PXPd), to give the corresponding boronate ester 2-H2NC6H4(BO2C2Me4) in excellent yields. The PXPd system could also be used in the catalyzed borylation of substituted anilines to give the corresponding aminoboronate esters in moderate to high yields.
- Wheaton, Susan L.,Kabir, S.M. Humanayun,Zhang, Haiwen,Vogels, Christopher M.,Decken, Andreas,Westcott, Stephen A.
-
experimental part
p. 725 - 731
(2011/11/04)
-
